Medical Foster Homes Provide More Independence for Aging Veterans
http://www.csa.us/email/spirit/ssarticles/0812Lifestyle.html
For aging veterans who want more independence than a nursing home provides and who want to remain in a home setting, the U.S. Department of Veterans Affairs (VA) offers a new option: a foster care home. It works well for the senior, the caregiver and the VA. Click here to view article.
Estate Sales: Sellers Beware
Although estate sales are becoming a popular way to get rid of possessions, especially when having to downsize, the industry is unregulated, so sellers, as well as buyers, need to be cautious. Click here to view article.
http://www.csa.us/email/spirit/ssarticles/0812MedNews.html
State policymakers are busy figuring out how to handle health issues for seniors. Not surprisingly, No. 1 on their list is increasing enrollment in Medicaid in the face of diminishing federal funds. But policymakers are also worried that there won’t be enough healthcare workers to care for the huge baby boomer population. Click here to view article.
Join us on Saturday, September 8 for this fun family event along the Riverwalk in Naperville, IL. For details, go to www.apdamidwest.org
Event Schedule
8:30 a.m. Check-in
Turn in pledge sheets and donations.
Make suggested minimum donation of $25 per person and receive one t-shirt.
Sign waiver for walking.
Enjoy coffee and snacks.
9:30 a.m. Welcome
Maxine Dust, APDA Midwest Chapter Board President: Opening Remarks
Dr. Michael Rezak: Update on PD research
10:00 a.m. Walk begins
11:00 a.m. Raffle drawing
Fresh cooked hot dog lunch for sale for $3 including chips and can of pop.
You should have received your pledge sheet with your newsletter. to collect and record pledges and turn it all in at check-in. If you are unable to attend the Walk, make donations on line at www.apdamidwest.org
For more information, call the Midwest Chapter Office at 630-933-4392.
Solanezumab Phase 3 Clinical Trial Results Bring New and Encouraging Information
http://www.businessweek.com/ap/2012-08-24/lilly-alzheimers-drug-trial-yields-promising-sign
Eli Lilly and Company announced today that two Phase 3 studies of an experimental drug therapy called solanezumab in mild to moderate Alzheimer’s disease did not meet their primary endpoints.
However, there is new and encouraging information in the trial results. According to the company, in a secondary pooled analysis of both studies, the drug at the tested dose showed a statistically significant slowing of cognitive decline in people with mild to moderate Alzheimer’s disease; the results were driven by people with mild Alzheimer’s. If this finding can be duplicated, it suggests that an Alzheimer’s therapy targeting beta amyloid can have a beneficial effect on cognitive abilities in people with mild to moderate Alzheimer’s. That would be a major step forward in the fight against Alzheimer’s disease.
Another hopeful sign is that, according to the company, an open label extension study of this drug will continue. This means that people who were in the Phase 3 trials will have an opportunity to continue taking the drug. This will give us further insight into the effects of this drug over a longer period of time, and also into the value of amyloid-based therapies for people with Alzheimer’s.
The company has only reported “topline” results at this time. More details will be available at the American Neurological Association annual meeting in early October. The company also says that “next steps for solanezumab have not yet been decided and will be determined after discussions with regulators.” The Alzheimer’s Association looks forward to seeing the full data from these studies, and also hearing about the company’s discussions with the FDA about next steps for this drug.